Benign Prostatic Hyperplasia and Glycosaminoglycan

Prostatic Hyperplasia Clinical Trial

Official title:

The Relationship of Lower Urinary System Symptoms Due to Benign Prostatic Hyperplasia and Urinary Glycosaminoglycan Level

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03955484
• Other study ID #: MAR.UAD.005
• Status: Recruiting
• Start date: April 1, 2019
• Est. completion date: November 1, 2019

Study information

• Verified date: May 2019
• Source: Marmara University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lower urinary tract symptoms (LUTS) are one of the most common conditions in the urology clinic, affecting at least one in four men after 40 years of age. Benign prostatic hyperplasia is the most common cause of LUTS. Bladder dysfunction (hypersensitivity or detrusor overactivity) and bladder outlet obstruction are two main pathologies involved in the etiology of LUTS. In men aged 40-49, moderate and severe LUTS are reported as 26%, while this ratio is doubled in the age group of 70 years and older. Clinically, BPH is defined as an international symptom score of more than 8, a prostate volume of more than 30 ml, and a maximum flow rate of less than 15 ml / sec. Alpha blockers are recommended as the first-line medical treatment according to European Urology Guidelines (EAU Guidelines 2018) for patients diagnosed with BPH clinically. In recent years, many studies have been published on the relationship of urinary biomarkers with LUTS. Nerve growth factor and brain derived neurotrophic factor have been shown to be closely related to neurogenic or non-neurogenic detrusor overactivity and significant improvements were observed after treatment.The relationship between urinary glycosaminoglycan and overactive bladder has been shown and it has been reported that the values have decreased after treatment.Male patients with LUTS caused by BPH often have symptoms of overactive bladder. However, as far as we know, there is no study in the literature about the meaning of urinary GAG levels in this patient group. The aim of this study was to investigate the relationship between urinary glycosaminoglycan levels and patients who had benign prostatic hyperplasia with and without overactive bladder symptoms.

Description:

35 patients and 10 controls were planned to be included in the study. Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method. Urine GAG levels and pre and post treatment uroflowmetry, IPSS, overactive bladder symptom score, bladder frequency volume chart, post void residual urine volume will be compared.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: November 1, 2019
• Est. primary completion date: September 1, 2019
• Gender: Male
• Age group: 40 Years to 70 Years

Eligibility

Eligibility Criteria

1. Male patients presenting with lower urinary tract symptoms to urology outpatient clinic

2. According to the European Association of Urology Guidelines:

1. International prostate symptom score> 8

2. Prostate volume> 40 ml

3. Q max <15 ml /sn

3. Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time

4. Patients who have not undergone lower urinary tract surgery

Exclusion Criteria

1. Patients who had undergone medical and surgical treatment for lower urinary tract symptoms

2. Patients with accompanying urethral stricture

3. Patients with neurological diseases (Parkinson's, Multiple Sclerosis etc ...)

4. Patients with spinal cord trauma

5. Patients with indication for surgical treatment at the time of initial admission (Macroscopic hematuria, bladder stone, urinary retention, upper urinary tract dilatation)

Related Conditions & MeSH terms

• Hyperplasia
• Prostatic Hyperplasia

Intervention

Diagnostic Test:
• Urinary Glycosaminoglycan
Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.

Locations

Country	Name	City	State
Turkey	Marmara University	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Marmara University

Country where clinical trial is conducted

Turkey, 

References & Publications (6)

Alkis O, Zumrutbas AE, Toktas C, Aybek H, Aybek Z. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment? Neurourol Urodyn. 2017 Feb;36(2):390-393. doi: 10.1002/nau.22939. Epub 2015 Dec 10. — View Citation

Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J. 2013 Jul;24(7):1065-72. doi: 10.1007/s00192-012-2027-1. Epub 2013 Jan 12. Review. Erratum in: Int Urogynecol J. 2013 Oct;24(10):1775-6. — View Citation

Mashima R, Sakai E, Tanaka M, Kosuga M, Okuyama T. The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry. Mol Genet Metab Rep. 2016 Apr 22;7:87-91. doi: 10.1016/j.ymgmr.2016.03.009. eCollection 2016 Jun. — View Citation

Siracusano S, Cucchi A, Ciciliato S, Lampropoulou N, Vittur F. Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec;20(12):1477-80. doi: 10.1007/s00192-009-0973-z. Epub 2009 Aug 12. — View Citation

Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, Lee KS. Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients. Int Neurourol J. 2017 Dec;21(4):270-281. doi: 10.5213/inj.1732794.397. Epub 2017 Dec 31. — View Citation

Wang LW, Han XM, Chen CH, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol. 2014 Feb;46(2):341-7. doi: 10.1007/s11255-013-0540-x. Epub 2013 Aug 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The value of glycosaminoglycan in predicting the success of medical treatment of benign prostatic hyperplasia		one month